---
title: "Barclays Remains a Buy on Oruka Therapeutics (ORKA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286389801.md"
description: "Barclays analyst Etzer Darout has maintained a Buy rating on Oruka Therapeutics (ORKA) with a price target of $160.00. Darout, a 5-star analyst with a 26.4% average return and 56.04% success rate, focuses on the Healthcare sector. The consensus on Oruka Therapeutics is a Strong Buy, with an average price target of $128.50."
datetime: "2026-05-14T09:17:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286389801.md)
  - [en](https://longbridge.com/en/news/286389801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286389801.md)
---

# Barclays Remains a Buy on Oruka Therapeutics (ORKA)

Barclays analyst Etzer Darout maintained a Buy rating on Oruka Therapeutics today and set a price target of $160.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Darout is a 5-star analyst with an average return of 26.4% and a 56.04% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Oruka Therapeutics is a Strong Buy with an average price target of $128.50.

### Related Stocks

- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)
- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)